269 North Mathilda Avenue
About PQ BypassPQ Bypass, Inc. is a Silicon Valley-based medical device company working to transform the treatment of long-segment peripheral artery disease with minimally-invasive endovascular solutions.
PQ Bypass is a former Company-In-Residence at the Fogarty Institute for Innovation and is operated by recognized leaders in the medical device industry. Our executive team members have held senior leadership positions at companies including Medtronic, Abbott, Johnson & Johnson, Covidien, and Stryker and also have extensive experience developing medical devices for startups such as Evalve, AccessClosure, Altura, Avinger, and DVI.
CEO: Peter Wehrly
Please click here for PQ Bypass job opportunities.
19 articles with PQ Bypass
PQ Bypass Releases Positive 24-Month Data from the DETOUR1 Clinical Trial for Percutaneous Femoropopliteal Bypass at VIVA 2020
Promising long-term safety and effectiveness results from PAD population with extremely complex SFA disease
PQ Bypass Completes Enrollment in DETOUR2 Percutaneous Femoral-Popliteal Bypass Pivotal Study for Patients With Complex Peripheral Arterial Disease
PQ Bypass, an innovative medical device company pioneering advancements in the treatment of complex peripheral artery disease (PAD), announces enrollment of the final subject in the company’s flagship IDE, the DETOUR2 clinical trial. This important milestone occurs only a month after the Detour System entered the U.S. Food and Drug Administra
PQ Bypass, Inc., a medical device company pioneering innovative advancements in the treatment of complex Peripheral Artery Disease (PAD), names Heather Simonsen as its President. With this appointment, PQ Bypass now outperforms 90% of Health Technology companies with regards to women representation at the ex
PQ Bypass, a medical device manufacturer based in California, announced that DETOUR2 will take the stage during the 10th Annual Amputation Prevention Symposium, the leading meeting dedicated to the treatment and prevention of critical limb ischemia.
PQ Bypass Inc, a medical device company bringing new advancements to the treatment of peripheral artery disease (PAD), announced today that it has received approval for coverage from the Centers for Medicare and Medicaid Services (CMS) for the Investigational Device Exemption (IDE) study titled TORUS 2
CORRECTING and REPLACING PHOTO PQ Bypass Initiates Pivotal Study of Next-Generation Advancement in Stent Graft Technology for Treatment of Patients with Peripheral Artery Disease
PQ Bypass, Inc., a clinical-stage medical device company, announced it has enrolled the first patient in its TORUS 2 multi-center clinical trial of its self-expanding TORUS® stent graft system, a novel technology designed for the treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA).
PQ Bypass Initiates Pivotal Study of Next-Generation Advancement in Stent Graft Technology for Treatment of Patients with Peripheral Artery Disease
PQ Bypass, Inc. announced it has enrolled the first patient in its TORUS 2 multi-center clinical trial of its self-expanding TORUS® stent graft system, a novel technology designed for the treatment of peripheral artery disease in the superficial femoral artery This inaugural enrollment comes less than a month after the study received unconditional approval from the FDA for the TORUS 2 original IDE.
PQ Bypass Announces Unconditional IDE Approval From U.S. FDA to Start TORUS SFA Stent Graft Pivotal Study (TORUS-2)
TORUS-2 marks second Investigational Device Exemption approved for company in less than two years.
PQ Bypass Announces $60 Million Financing to Advance New Therapeutic Approach to Peripheral Arterial Disease
Funds Will Support Pivotal Trial of Novel DETOUR System Designed for Patients with Tough to Treat Long Blockages in Leg Arteries
Highly Respected Industry Veteran to Provide Expertise and Counsel.
PQ Bypass Reports Positive 12-Month Results for Entirely New Procedure to Treat Extremely Long SFA Lesions in Patients with PAD
DETOUR I Trial Presented during SVS Vascular Annual Meeting 2018 Late Breaking Clinical Trial Session
PQ Bypass Announces First Patient Treated in Landmark DETOUR II Trial Evaluating New Treatment Approach for Clogged Leg Arteries
PIVOTAL Trial Now Underway in the United States for First-of-its-Kind Procedure in Patients with Severe Peripheral Artery Disease (PAD)
PQ Bypass Receives IDE Approval to Initiate Study of First-of-its-Kind Procedure for Patients Suffering From Peripheral Artery Disease
PQ Bypass, today announced it has received conditional approval of its investigational device exemption (IDE) from the FDA to initiate the pivotal DETOUR II clinical trial.
PQ Bypass Reports Positive Results For The Novel DETOUR System In Patients With Tough To Treat Long Blockages In The Femoropopliteal Artery